Korro to Present at the Jefferies London Healthcare Conference
Korro Bio (Nasdaq: KRRO) has announced its participation in the Jefferies London Healthcare Conference. CEO and President Ram Aiyar will deliver a presentation on November 19, 2024, at 8:00 a.m. GMT, accompanied by CFO Vineet Agarwal and Chief Medical Officer Kemi Olugemo. The company, which specializes in developing RNA-editing genetic medicines for rare and prevalent diseases, will provide a live webcast of the presentation through their website. A replay will be available for 30 days following the event.
Korro Bio (Nasdaq: KRRO) ha annunciato la sua partecipazione alla Jefferies London Healthcare Conference. Il CEO e Presidente Ram Aiyar presenterà il 19 novembre 2024, alle 8:00 GMT, accompagnato dal CFO Vineet Agarwal e dal Chief Medical Officer Kemi Olugemo. L'azienda, specializzata nello sviluppo di medicine genetiche per la modifica dell'RNA destinate a malattie rare e diffuse, fornirà una trasmissione in diretta della presentazione attraverso il proprio sito web. Una registrazione sarà disponibile per 30 giorni dopo l'evento.
Korro Bio (Nasdaq: KRRO) ha anunciado su participación en la Jefferies London Healthcare Conference. El CEO y Presidente Ram Aiyar realizará una presentación el 19 de noviembre de 2024, a las 8:00 a.m. GMT, acompañado por el CFO Vineet Agarwal y la Directora Médica Kemi Olugemo. La empresa, que se especializa en el desarrollo de medicamentos genéticos de edición de ARN para enfermedades raras y prevalentes, ofrecerá una transmisión en vivo de la presentación a través de su sitio web. Una repetición estará disponible durante 30 días después del evento.
Korro Bio (Nasdaq: KRRO)는 제프리스 런던 헬스케어 컨퍼런스에 참여할 것이라고 발표했습니다. CEO이자 회장인 Ram Aiyar가 2024년 11월 19일 오전 8:00 GMT에 CFO인 Vineet Agarwal 및 최고 의료 책임자인 Kemi Olugemo와 함께 발표를 진행할 예정입니다. 이 회사는 희귀 및 일반 질병을 위한 RNA 편집 유전 의약품 개발을 전문으로 하며, 웹사이트를 통해 발표의 생중계를 제공할 것입니다. 이벤트 후 30일 동안 다시 보기 서비스가 제공됩니다.
Korro Bio (Nasdaq: KRRO) a annoncé sa participation à la Jefferies London Healthcare Conference. Le PDG et président Ram Aiyar fera une présentation le 19 novembre 2024, à 8h00 GMT, accompagné du directeur financier Vineet Agarwal et de la responsable médicale Kemi Olugemo. L'entreprise, qui se spécialise dans le développement de médicaments génétiques d'édition d'ARN pour des maladies rares et répandues, fournira une diffusion en direct de la présentation via son site web. Un enregistrement sera disponible pendant 30 jours après l'événement.
Korro Bio (Nasdaq: KRRO) hat seine Teilnahme an der Jefferies London Healthcare Conference bekannt gegeben. CEO und Präsident Ram Aiyar wird am 19. November 2024 um 8:00 Uhr GMT zusammen mit CFO Vineet Agarwal und Chief Medical Officer Kemi Olugemo eine Präsentation halten. Das Unternehmen, das auf die Entwicklung von RNA-bearbeitenden Gentherapien für seltene und verbreitete Krankheiten spezialisiert ist, wird die Präsentation über seine Website live übertragen. Eine Wiederholung wird 30 Tage nach der Veranstaltung verfügbar sein.
- None.
- None.
CAMBRIDGE, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today announced that Ram Aiyar, Ph.D., Chief Executive Officer and President, will present at the Jefferies London Healthcare Conference on Tuesday, November 19, 2024, at 8:00 a.m. GMT. Vineet Agarwal, Chief Financial Officer, and Kemi Olugemo, M.D., FAAN, Chief Medical Officer, will also be participating at the conference.
A live webcast of the presentation can be accessed on the "Events & Presentations" page in the Investor section of Korro’s website at www.korrobio.com. Following the presentation, a replay of the event will be available for 30 days.
About Korro
Korro is a biopharmaceutical company focused on developing a new class of genetic medicines for both rare and highly prevalent diseases using its proprietary RNA editing platform. Korro is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to affect a precise yet transient single base edit. By editing RNA instead of DNA, Korro is expanding the reach of genetic medicines by delivering additional precision and tunability, which has the potential for increased specificity and improved long-term tolerability. Using an oligonucleotide-based approach, Korro expects to bring its medicines to patients by leveraging its proprietary platform with precedented delivery modalities, manufacturing know-how, and established regulatory pathways of approved oligonucleotide drugs. Korro is based in Cambridge, Massachusetts. For more information, visit korrobio.com.
Korro Contact Information
Investor & Media Contact
Tim Palmer
IR@korrobio.com
FAQ
When will Korro Bio (KRRO) present at the Jefferies London Healthcare Conference 2024?
How can I watch Korro Bio's (KRRO) presentation at the Jefferies Conference?
How long will the replay of Korro Bio's (KRRO) Jefferies Conference presentation be available?
Which Korro Bio (KRRO) executives will participate in the Jefferies London Healthcare Conference?
